WSI Reports 13 Billion KRW in Q2 Sales, Up 53.7% Year-on-Year
WSI announced on August 18 that it achieved significant year-on-year growth in scale in the second quarter, driven by the consolidated performance of its subsidiary, IntroBioPharma.
On a consolidated basis, WSI reported second-quarter sales of 13 billion KRW and operating profit of 1.1 billion KRW. Sales and operating profit increased by 53.7% and 16.4%, respectively, compared to the same period last year. However, net profit for the period recorded a deficit of 2.4 billion KRW due to losses from the valuation of derivatives related to convertible bonds (CB). This loss is an accounting expense that does not affect actual cash flow.
This quarter's growth in scale is also attributed to the consolidation effect of its subsidiary, IntroBioPharma. IntroBioPharma is a pharmaceutical company specializing in research, development, and manufacturing, with strengths in treatments for circulatory and metabolic diseases. WSI's core business of pharmaceutical and medical device distribution also continues to deliver stable results every quarter.
A company representative stated, "The strong year-on-year growth was possible as the full performance of IntroBioPharma, acquired in June last year, was reflected in the second quarter. Despite the overall stagnation in the healthcare market, our core business in pharmaceutical and medical device distribution-including topical hemostatic agents and adhesion barriers-continues to deliver stable results, backed by a robust sales network."
The representative added, "Going forward, we will continue to expand synergies between our stable medical device distribution business and pharmaceutical manufacturing, while strengthening future growth engines through our medical robotics business."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
Meanwhile, WSI's subsidiary EasyMediBot is currently undergoing approval procedures with the Ministry of Food and Drug Safety, aiming to launch the world's first gynecological assistive robot, 'U-BOT,' in the first half of 2026. The company also plans to expand its surgical robot portfolio with devices such as the B-BOT for brain and nerve surgery and the C-BOT for cardiovascular diseases.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
